CP
ALXN

Castleview Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Castleview Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$3K Buy
+17
New +$2.92K ﹤0.01% 851

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Castleview Partners's ALXN Position: Q2 2021 in Review

Castleview Partners opened a new position in Alexion Pharmaceuticals (ALXN) in Q2 2021: 17 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #851 among its holdings.

707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Castleview Partners held 17 shares of Alexion Pharmaceuticals worth $3K as of Q2 2021.
  • Alexion Pharmaceuticals was a new Castleview Partners position in Q2 2021.
  • Alexion Pharmaceuticals made up ﹤0.01% of Castleview Partners's portfolio in Q2 2021, its #851 holding.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Castleview Partners's 13F filing for Q2 2021, filed 17 Aug 2021.